The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry
NCT ID: NCT02264912
Last Updated: 2020-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2016 participants
OBSERVATIONAL
2008-07-31
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization
NCT03953547
Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
NCT05730114
Anticoagulant Treatments and Percutaneous Coronary Angioplasty
NCT00669149
Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition
NCT00302913
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES
NCT02079194
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
stent-PCI patients
Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.
antiplatelet drugs - P2Y12 antagonists
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
antiplatelet drugs - P2Y12 antagonists
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Faculty Hospital Kralovske Vinohrady
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zuzana Motovska
Associate Professor, MD. PhD. FESC.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zuzana Motovska, MD.PhD.
Role: PRINCIPAL_INVESTIGATOR
Faculty Hospital Kralovske Vinohrady
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty Hospital Kralovske Vinohrady
Prague, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Motovska Z, Odvodyova D, Fischerova M, Stepankova S, Maly M, Morawska P, Widimsky P. Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention. Am J Cardiol. 2012 Mar 1;109(5):620-3. doi: 10.1016/j.amjcard.2011.10.019. Epub 2011 Dec 10.
Motovska Z, Ondrakova M, Doktorova M, Widimsky P. Severe left ventricular systolic dysfunction is independently associated with high on-clopidogrel platelet reactivity. Am J Cardiovasc Drugs. 2014 Aug;14(4):313-8. doi: 10.1007/s40256-014-0074-3.
Ondrakova M, Knot J, Ulman J, Maly M, Motovska Z. Efficacy of P2Y12 receptor antagonists in patients with atrial fibrillation according to the CHA2DS2VASc score. Int J Cardiol. 2016 Mar 15;207:84-6. doi: 10.1016/j.ijcard.2016.01.039. Epub 2016 Jan 6. No abstract available.
Motovska Z, Ondrakova M, Bednar F, Knot J, Ulman J, Maly M. Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry. Thromb Res. 2015 Jun;135(6):1093-9. doi: 10.1016/j.thromres.2015.04.014. Epub 2015 Apr 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05-2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.